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Abstract In chronically uncompensated diabetes mellitus,
an increase has been observed in the content of advanced
glycation endproduct (AGE)-modified proteins in various
tissues, including bone. This increase can lead to a local
imbalance in the secretion of cytokines and growth factors,
and has been implicated in the pathophysiology of the long-
term complications of diabetes. We have previously shown
that the proliferation and differentiation of UMR106 rat
osteosarcoma and MC3T3E1 mouse calvaria-derived cell
lines are regulated by AGE-modified proteins, possibly
through the recognition of these AGEs by specific mem-
brane-associated receptors. In the present study, we investi-
gated the effects of AGE-proteins on the secretion of
insulin-like growth factor-I (IGF-I) and its binding proteins
(IGFBPs) by both osteoblast-like cell lines. In the case of
MC3T3E1 cells, this was studied throughout their succes-
sive stages of development: proliferation, differentiation and
mineralisation. For every condition, cells were incubated 24
hours with increasing concentrations of either bovine serum
albumin (BSA) or AGE-BSA. IGF-I in conditioned media
was separated from IGFBPs by acid gel filtration-centrifu-
gation, and measured by radioimmunoassay. IGFBPs in
conditioned media were analysed by a semi-quantitative
western ligand blot. In UMR106 cells, low doses of AGE-
BSA significantly decreased the secretion of both IGF-I
(56% of control) and a 24 kDa IGFBP (80% of control).
Results for MC3T3E1 cells, which predominantly secrete 29
kDa IGFBPs, were dependent on the stage of development.
In proliferating preosteoblastic cells, AGE-BSA decreased
the secretion of IGF-I (34%–37% of control) while increas-
ing the secretion of IGFBP (124%–127% of control). On the
other hand, secretion of these components of the IGF system
by mature (differentiated) cells was unaffected by the pres-
ence of AGE-BSA. When these cells finally attained miner-
alisation, incubation with AGE-modified BSA provoked an
increase both in IGFBP (131%–169% of control) and in
IGF-I secretion (119%–123% of control). The presented evi-
dence suggests that the modulation of growth and develop-
ment by AGE-modified proteins, previously described for
both cell lines, could be the result of an autocrine-paracrine
mechanism involving the IGF-IGFBP system.
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Introduction
An increasing body of evidence has recently accumulated to
suggest that the development and progression of both micro-
and macrovascular complications of diabetes could be due to
the excessive formation of advanced glycation endproducts
(AGEs) of proteins [1]. These post-translational modifications
of proteins are derived nonenzymatically. In one of the pro-
posed mechanisms for the formation of AGE, a reducing sugar
such as glucose reacts with a free amino group of a protein,
Acta Diabetol (2001) 38:113–122 © Springer-Verlag 2001
A.D. McCarthy • S.B. Etcheverry • A.M. Cortizo
Effect of advanced glycation endproducts on the secretion of insulin-like
growth factor-I and its binding proteins: role in osteoblast development
Received: 15 September 2000 / Accepted in revised form: 23 August 2001
O R I G I N A L
A.D. McCarthy • S.B. Etcheverry • A.M. Cortizo (Y)
Department of Pathological Biochemistry
Facultad de Cencias Exactas
Universidad Nacional de la Plata
Calle 47 y 115, 1900 La Plata, Argentina
giving rise to a Schiff base, which through an intramolecular
rearrangement can form a more stable, but still freely
reversible, molecule: the Amadori product. Eventually,
Amadori products can irreversibly progress to a family of
compounds, collectively known as AGEs, many of which are
fluorescent or participate in the formation of protein crosslinks
[2]. Thus, nonenzymatic glycosylation can alter both the struc-
ture and bioactivity of the affected proteins [3–6]. In addition,
the AGE moieties can be specifically recognised by plasma
membrane receptors, which have been described in cells from
various tissues [7–10]. The occupation of these receptors by
AGEs in some cell types induces the secretion of cytokines
and growth factors, which in turn can lead to an alteration in
the proliferation and differentiation of nearby cells [11, 12].
Young developing patients with type 1 diabetes mellitus
who show persistent hyperglycaemia throughout their
growth stages frequently present a deficit in bone mass,
which can eventually lead to a delay in maturation or to
growth impairment [13–15]. These effects appear to be asso-
ciated with a failure to acquire sufficient endosteal bone, and
with complex vascular, nutritional and hormonal factors [16,
17]. Several lines of research have recently suggested that
AGE accumulation could be involved in the diabetes-associ-
ated bone alterations. AGE-modified collagen has been
shown to increase in the bones of diabetic rats, in relation to
the duration of disease [18, 19]. In addition, the formation of
AGE on bone matrix diminishes its ability to induce bone
formation [20]. AGE-modified proteins have also been found
to enhance osteoclast-induced bone resorption [21], to stim-
ulate interleukin-6 (IL-6) production by human bone-derived
cells [22] and to dose-dependently inhibit the phenotypic
expression of a primary culture of rat osteoblasts and of pre-
osteoblastic UMR201-10B cells [19, 23]. In keeping with
these results, our group has demonstrated that AGE-modified
proteins regulate the growth of mouse MC3T3E1 and rat
UMR106 osteoblastic cell lines: while initially eliciting an
increase in cellular proliferation and differentiation, a rela-
tively long-term incubation of these cells with AGE-modi-
fied proteins induces a significant decrease in both parame-
ters [24]. Furthermore, we have recently described the pres-
ence of membrane-associated receptors in both cell lines,
which specifically participate in the recognition and degra-
dation of AGE-modified proteins [10].
The physiological process of bone growth and develop-
ment is strongly influenced, in autocrine and paracrine man-
ners, by the insulin-like growth factors (IGF-I and IGF-II)
and their binding proteins (IGFBPs). These polypeptides are
produced by osteoblasts [25, 26], and are present in bone
matrix [27, 28]. In vitro, IGFs can modulate the expression
of osteoblastic phenotype [29, 30], and stimulate the prolif-
eration of osteoblasts in culture [31]. In vivo, exogenously
added IGFs lead to an increase in bone formation and tra-
becular bone mass [32]. In addition, multiple IGFBPs mod-
ulate the actions of IGFs [33, 34]. In fact, the relative abun-
dance of IGFBPs, as well as their affinity for IGFs, most
probably determine the bioactivity of IGFs on bone growth
and development [35]. Recently, an association has been
found between the progressive osteoblastic differentiation
of MC3T3E1 cells, and temporal changes in their expression
of IGF-I and IGFBPs [36]. This association implicates the
IGF system in an autocrine-paracrine regulation of
osteoblastic growth and development.
In the present study, we investigated the possible partic-
ipation of the IGF system in the AGE-dependent modulation
of osteoblastic growth and differentiation. In consequence,
we examined the influence of AGE on the secretion of IGF-
I and IGFBPs by rat UMR106 and mouse MC3T3E1 cells in




Rabbit polyclonal antibody against human IGF-I (UBK487) was a
generous gift from Dr. L. E. Underwood (Division of Paediatric
Endocrinology, University of North Carolina at Chapel Hill, USA).
Recombinant human IGF-I, bovine serum albumin (BSA), phenyl-
methyl-sulphonyl-fluoride (PMSF), p-nitrophenyl-phosphate
(pNPP), glucose-6-phosphate (G6P), Triton X-100, acrylamide,
sodium dodecyl sulphate (SDS), prestained molecular weight stan-
dards, Kodak XAR-5 photographic film and Sephadex G-50 were
purchased from Sigma (St. Louis, MO, USA). Bio-Gel P-10 was
obtained from Bio-Rad Laboratories (Hercules, CA, USA).
Nitrocellulose paper was purchased from MSI (Westboro, MA,
USA). Dulbecco’s modified Eagle’s medium (DMEM) and trypsin-
EDTA were from Gibco (Life Technologies, Grand Island, NY,
USA). Fetal bovine serum (FBS) was purchased from Gen (Buenos
Aires, Argentina). Centricon 10 kDa cutoff filter cartridges were
from Amicon (Beverly, MA, USA). 125I was from New England
Nuclear. All other chemicals were of analytical grade.
Preparation of AGE-protein
AGE-BSA was prepared as we have previously described [24].
Briefly, BSA was incubated in sterile conditions in 150 mM phos-
phate-buffered saline (PBS), pH 7.4, with 100 mM G6P at 37º C for
6 weeks in the presence of protease inhibitors (1.5 mM PMSF) and
antibiotics (100 U/ml penicillin, 100 mg/l streptomycin). Control
BSA was incubated under the same conditions without G6P. At the
end of the incubation period, BSA and AGE-BSA were separated
from non-covalently bound low molecular weight molecules by cen-
trifugation-filtration with Centricon filter cartridges. The formation of
protein-AGEs was assessed by their characteristic fluorescence-emis-
sion maximum at 420 nm upon excitation at 340 nm. Fluorescence
values of test substances were expressed as percentage relative fluo-
rescence. Thus, the estimated level of AGE-BSA obtained in this in
vitro incubation was 18.5% relative fluorescence intensity per mil-
ligram protein, as opposed to 3.2% for control BSA.
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Cell culture
MC3T3E1 osteoblastic mouse calvaria-derived cells were grown in
75 cm2 plastic flasks at 37º C in a humidified 5% CO2 atmosphere
in DMEM supplemented with 10% FBS, 100 U/ml penicillin and
100 mg/l streptomycin, and passaged every 4–6 days. Previous
studies have demonstrated that expression of osteoblastic markers
begins after culturing these cells for 10 days with medium supple-
mented by β-glycerol-phosphate and ascorbic acid. In addition,
mineralisation is achieved with these cells after extending this cul-
ture to 25 days. However, the cells only undergo active replication
during the first 10 days of incubation [36, 37]. Thus, in order to
study the secretion of IGF-I and IGFBPs in the different stages of
this cell line, different protocols were chosen. To obtain pre-
osteoblastic cells in active proliferation, cells were plated in
24–well plates (2.0x104 cells/well) and cultured for 3 days in
DMEM with 10% FBS. In other experiments, MC3T3E1 cells were
plated in 24–well plates (2.0x104 cells/well), and cultured in
DMEM supplemented with 10% FBS, 5 mM β-glycerol-phosphate
and 25 mg/l ascorbic acid for either 15 days (differentiated cells) or
25 days (mineralising cells), changing the medium every 2 days. At
the end of all incubations, cells were serum deprived, washed with
DMEM and cultured for 24 hours with different concentrations of
either control BSA or AGE-BSA. Conditioned media were saved
for evaluation of cellular IGF-I and IGFBP secretion as described
successively. The cell monolayer was lysed with 0.5 ml 0.1% Triton
X-100. Aliquots of this total cell extract were then employed for
protein determination using the Bradford method [38] and for
measurement of the osteoblastic differentiation marker alkaline
phosphatase (ALP) using pNPP as substrate [24]. In other experi-
ments, the formation of mineralised nodules was microscopically
evaluated in 15- and 25-day cultures of MC3T3E1 cells by the von
Kossa technique [39]. Briefly, cells were fixed in 10% neutral
buffered formalin and stained with 3% AgNO3 for 30 min.
UMR106 rat osteosarcoma-derived cells were grown in
DMEM with 10% FBS and antibiotics. This cell line has been
shown to conserve certain characteristics of differentiated
osteoblastic phenotype [40]. After 5–7 days, cells were sub-cul-
tured using trypsin-EDTA and replated to begin the experiments.
Cells were split at subconfluence and plated in 24–well plates
(2.5x104 cells/well) in DMEM with 10% FBS. Subconfluent cells
were then serum deprived, washed with DMEM and incubated for
24 hours with increasing concentrations of either control BSA or
AGE-BSA. Conditioned media and cell monolayers were
processed as described for MC3T3E1 cells, in order to evaluate
cellular production of IGF-I and IGFBPs, and cell-associated ALP
activity.
IGF-I assay
IGF-I content of conditioned media was determined by a specific
radioimmunoassay (RIA) as we have previously described [41].
IGFBPs were previously eliminated from the samples by a recent-
ly described acid gel filtration-centrifugation method [42]. Briefly,
conditioned media were dried in a Savant Speed-Vac centrifuge,
dissolved in 100 µl elution buffer (1 M acetic acid, 0.1 M NaCl)
and applied to a minicolumn loaded with 4 ml BioGel P-10 (45- to
90-µl particle size) hydrated with elution buffer containing 10 g/l
BSA. Void volume was discarded by centrifugation at 1250 x g for
5 minutes, and IGFBPs were eliminated by application of 250 µl
elution buffer and further centrifugation for 5 minutes. IGF-I was
recovered from the column by elution-centrifugation with 1.5 µl elu-
tion buffer. This IGF-containing fraction was then neutralised and
dried by Speed-Vac centrifugation. Samples were stored at -20º C
until IGF-I RIA was performed.
In order to validate this method for our assay conditions,
125I-IGF-I was added to a serum sample diluted in elution-buffer
prior to extraction. The sample was applied to a column and then
eluted in a stepwise manner, by successive elution-centrifugation
with 10x50 µl and 10x250 µl aliquots of buffer. In each aliquot, the
125I-IGF-I-associated radioactivity, as well as total IGF-I binding
capacity [42], were measured to determine the elution volumes
which optimally separate IGFs from IGFBPs (Fig. 1). The recov-
ery of exogenously added 125I-IGF-I was greater than 90%. No
IGFBPs from the serum sample were detected by binding capacity
analysis of the IGF-I pool obtained by BioGel separation.
For assay purposes, recombinant-human IGF-I was used as a
standard and tracer in the RIA. The hormone was iodinated with
125I by means of the chloramine-T method [43] at a specific activ-
ity of 400–450 µCi/µg, and purified on a Sephadex G-50 column
[44]. The anti-IGF-I rabbit polyclonal antibody (UBK487) was
employed at 1:8000 dilution. The intra- and interassay coefficients
of variation for this method were 10.9% and 13%, respectively.
Under our working conditions, serial dilutions of rhIGF-I standard
(0.025–50 ng/tube) and extracted conditioned medium gave paral-
lel displacement curves. Levels of IGF-I in BSA-supplemented
non-conditioned serum-free culture media were below the detec-
tion limit.
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Fig. 1 Separation of IGF-I from IGFBPs in a serum sample by Bio-
Gel P-10 extraction. An aliquot of serum was mixed with 125I-IGF-
I and elution buffer. The sample was then applied to a minicolumn
containing hydrated BioGel P-10, and centrifuged for 5 minutes as
described in Materials and methods. The column was eluted
sequentially with 10x50 µl and 10x250 µl aliquots of elution buffer.
Each fraction was then subjected to the binding capacity assay to
evaluate total IGFBPs, and counted in a gamma counter for 125I-
IGF-I quantification
Western ligand blot for IGFBPs
Conditioned media were dried in a Savant Speed-Vac centrifuge, and
dissolved in 50 µl Laemmli’s non-reduced sample buffer [45] imme-
diately prior to electrophoresis. These samples were then boiled for 3
minutes before being loaded onto a 12.5% SDS-polyacrylamide gel.
Under these conditions, endogenous IGFs are dissociated by SDS, so
the molecular weight reflects that of the binding component alone.
Samples were electrophoresed at 150 V until the dye front reached
the bottom of the gel. Prestained molecular weight marker proteins
and a rat serum sample were run in parallel lanes. Proteins were
transferred to nitrocellulose membranes in a 15 mM Tris-base, 120
mM glycine buffer, pH 8.3, containing 5% methanol (v/v) [46].
Electroblotting was performed under constant current of 50 mA for
16–18 hours. The nitrocellulose paper was then blocked at 4º C [46]
and incubated with 125I-IGF-I (2x105 cpm/ml, as described previous-
ly) in 1% IGFBP-free BSA, 0.1% Tween-20 in TS buffer (150 mM
NaCl, 10 mM Tris-HCl, pH 7.4, 0.5 mg/ml sodium azide). Following
this incubation, the membranes were washed and autoradiographed
using XAR-5 Kodak film and a Dupont intensifying screen at -70º C
for 2–5 days. To measure the amount of 125I-IGF-I bound to each
IGFBP fraction, the nitrocellulose paper was cut into strips, which
were counted in a Cobra-II Packard gamma counter.
Statistical analysis
Four independent experiments were run by duplicate for each experi-
mental condition. Results are expressed as mean and SEM. Statistical
analysis of the data was performed employing Student’s t test.
Results
In order to characterise the successive stages of MC3T3E1
osteoblastic progression, cell-associated specific ALP activi-
ty was determined at all culture time points, and mineralisa-
tion was evaluated in 15- and 25-day cultures by staining cell
layers using the von Kossa method. In our culture conditions,
cellular ALP was undetectable in proliferating (3-day) pre-
osteoblasts, increased to 2.2±0.2 µmol pNP/min g protein in
mature (15-day) cells, and reached a plateau of 8.5±0.6 µmol
pNP/min g protein in long-term (25-day) cultures. In addi-
tion, von Kossa staining demonstrated the presence of extra-
cellular mineral nodules in 25-day cultures, indicating that
they had attained mineralisation (data not shown). This extra-
cellular mineral was absent in 15-day cultures.
In UMR106 cells, basal cell-associated ALP was 195±7
µmol pNP/min g protein. This established osteosarcoma cell
line expresses several markers of osteoblastic phenotype,
namely bone-specific ALP, type I collagen synthesis and
PTH-inducible cAMP levels [40].
We next studied the possible modulation of cellular IGF-
I secretion in UMR106 osteosarcoma cells, by a 24-hour
incubation with 100–500 µg/ml of AGE-modified BSA. In
these cells, the basal IGF-I secretion was 2.5±0.4 ng/mg
protein (n=8). AGE-BSA significantly decreased IGF-I
secretion at a concentration of 100 µg/ml (56%±8% of con-
trol BSA; p<0.05). At 200 and 500 µg/ml of AGE-modified
BSA, the secretion of IGF-I showed a tendency to decrease.
However, it was not significantly different from control
BSA (72%±19% and 80%±23% of basal levels, for 200 and
500 µg/ml, respectively).
In further experiments, we analysed the basal secretion
of IGF-I by MC3T3E1 cells throughout their successive
stages of development. Basal IGF-I secretion followed a
biphasic temporal pattern (Table 1). We also studied the pos-
sible modifications of IGF-I secretion as a consequence of a
24-hour incubation with AGE-BSA. When AGE-BSA was
incubated with preosteoblastic MC3T3E1 cells in active
proliferation (Fig. 2a), a significant decrease in IGF-I secre-
tion was observed at 200 and 500 µg/ml. In post-mitotic
MC3T3E1 cells with a mature phenotype (15-day differen-
tiated cultures), secretion of IGF-I was apparently unaffect-
ed by the presence of AGE-BSA vs. control BSA (105%,
80% and 83% of values from control BSA for 100, 200 and
500 µg/ml). On the contrary, IGF-I secretion by MC3T3E1
osteoblasts which had attained mineralisation (Fig. 2b) was
significantly increased when they were incubated with 100
and 200 µg/ml of AGE-BSA.
In the present experiments, when both cell lines were
incubated for 24 hours with 100–500 µg/ml AGE-modified
BSA, different effects were seen on their secretion of
IGFBPs, as assessed by western ligand blotting. In the case
of UMR106 osteosarcoma cells incubated with either AGE-
BSA or control BSA, ligand blot analysis showed the pre-
dominant secretion of a 24-kDa IGFBP and a minor 29-kDa
band (Fig. 3a). When the IGFBP bands corresponding to
each experimental condition were semiquantified (Fig. 3b),
a significant difference between AGE-BSA vs. control BSA
was found at a protein concentration of 100 µg/ml (80% of
control BSA).
In the non-transformed MC3T3E1 mouse calvariaderived
cell line, western ligand blot analysis showed a major band
of ~29 kDa. This pattern of IGFBP secretion, which most
probably was due to variable contributions by IGFBP-2 and
-5, was maintained throughout the successive stages of
MC3T3E1 osteoblastic development (Figs. 4a, 5a and 6a).
3-, 15- and 25-day cultures of MC3T3E1 cells were incubat-
ed with different concentrations of either AGE-BSA or control
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Table 1 Basal IGF-I secretion by MC3T3E1 osteoblast-like cells in
culture. Cells were incubated for 24 h with 100 µg/ml BSA in
DMEM. IGF-I was separated from IGFBP and measured by RIA.
Values are the mean (SEM) of four independent cultures performed
in duplicate
Cellular stage of development IGF-I (ng/mg cell protein)
Proliferated 10.3  (4.0)
Differentiated 3.5  (1.2)
Mineralised 24.0  (1.0)
A.D. McCarthy et al.: IGF-I and IGFBPs mediate AGE effects on bone 117
a b
Fig. 2a, b Effect of AGE-BSA on IGF-I secretion by cultures of MC3T3E1 cells in different developmental stages. a Proliferating
MC3T3E1. b Mineralised MC3T3E1. Osteoblast-like cells were cultured for different periods of time as described in Materials and meth-
ods. Cells were then incubated for 24 hours in serum-free DMEM with either BSA or AGE-BSA at the doses indicated in the figures.
Conditioned media were extracted and analysed to determine IGF-I concentration. Data are expressed as percent of control BSA and each
bar corresponds to the mean ± SEM (n=8). Differences between BSA and AGE-BSA are as follows: * p<0.02; ** p<0.002
Fig. 3a, b Effect of AGE-BSA on the secretion of IGFBPs in UMR106 cultures. a Cells were incubated in serum-free DMEM with either
BSA (lanes 1, 3 and 5) or AGE-BSA (lanes 2, 4 and 6) at protein concentrations of 100 µg/ml (lanes 1 and 2), 200 µg/ml (lanes 3 and 4)
or 500 µg/ml (lanes 5 and 6). After a 24-hour incubation, conditioned media were analysed for the presence of IGFBPs by western ligand
blotting employing 125I-IGF-I as a ligand. Lane 7, 10 µl rat serum. Bands were evidenced by autoradiography. b Nitrocellulose papers were
cut into strips and counted in a gamma counter for semi-quantification. The data for AGE-BSA is expressed as a percentage of the corre-
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Fig. 4a, b Effect of AGE-BSA on the secretion of IGFBPs in proliferating MC3T3E1 cultures. a Cells were incubated in serum-free DMEM
with either BSA (lanes 1, 3 and 5) or AGE-BSA (lanes 2, 4 and 6) at protein concentrations of 100 µg/ml (lanes 1 and 2), 200 µg/ml (lanes 3
and 4) or 500 µg/ml (lanes 5 and 6). After a 24-hour incubation, conditioned media were analysed for the presence of IGFBPs by western lig-
and blotting employing 125I-IGF-I as a ligand. Lane 7, 10 µl rat serum. Bands were evidenced by autoradiography. b Nitrocellulose papers were
cut into strips and counted in a gamma counter for semiquantification. Data for AGE-BSA are expressed as a percentage of the corresponding








Fig. 5a, b Effect of AGE-BSA on the secretion of IGFBPs in mature (differentiated) MC3T3E1 cultures. a Cells were incubated in serum-
free DMEM with either BSA (lanes 1, 3 and 5) or AGE-BSA (lanes 2, 4 and 6) at protein concentrations of 100 µg/ml (lanes 1 and 2), 200
µg/ml (lanes 3 and 4) or 500 µg/ml (lanes 5 and 6). After a 24-hour incubation, conditioned media were analysed for the presence of
IGFBPs by western ligand blotting employing 125I-IGF-I as a ligand. Lane 7, 10 µl rat serum. Bands were evidenced by autoradiography.
b Nitrocellulose papers were cut into strips and counted in a gamma counter for semiquantification. Data for AGE-BSA are expressed as








BSA for 24 hours. Conditioned media were then submitted to
ligand blotting, and the resulting IGFBP bands were semi-
quantified. In proliferating preosteoblastic cells (Fig. 4b),
AGE-BSA (100–500 µg/ml) significantly increased the
secretion of 29-kDa IGFBPs (124%–127% of control BSA).
On the other hand, AGE-BSA provoked no changes in total
29-kDa IGFBP production in 15-day cultures of MC3T3E1
cells (Fig. 5b). However, when AGE-BSA (200–500 µg/ml)
was incubated with cultures which had attained mineralisa-
tion (Fig. 6b), a biphasic stimulation was observed in the
secretion of 29-kDa IGFBPs (131%–169% of control BSA).
Discussion
The current study provides evidence that implicates AGE-
modified protein in the modulation of IGF-I and IGFBP
secretion by MC3T3E1 and UMR106 osteoblastic cells.
This modulatory effect was found to depend on the stage of
osteoblastic progression, and could be at least partly respon-
sible for the AGE-dependent changes in cellular prolifera-
tion and differentiation which we have previously described
in these cell lines [24].
It has been firmly established that the process of bone
formation depends on the number and activity of
osteoblasts, and on the activity of the IGF system [47]. Thus,
we hypothesised that the AGE-induced modulation of
osteoblastic cell growth, which we have previously
described [10, 24], could be mediated by regulating one or
more components of the locally produced IGF system.
The osteoblastic cell lines used in these experiments
have previously been found to secrete different IGFBPs.
UMR106 cells mainly synthesise IGFBP-4, a 24-kDa pro-
tein that inhibits IGF-I action in most systems [35, 48]. In
addition, they also produce lower amounts of a 29-kDa
binding protein, which has been shown to be IGFBP-5. In
this cell line, low concentrations (100 µg/ml) of AGE-BSA
significantly inhibited both IGF-I and 24-kDa binding pro-
tein (IGFBP-4) secretion. This is in agreement with our pre-
vious observation of AGE-BSA modulation of UMR106
cell proliferation [24], which also occurred in a narrow
range of concentrations. We have also shown in these cells
that this dose of AGE-BSA is sufficient to significantly
occupy cellular AGE-specific receptors [10] and is also
enough to provoke a long-term decrease in cellular prolif-
eration and ALP activity [24]. Thus, it is interesting to
speculate that in this cell line the AGE-mediated decrease
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Fig. 6a, b Effect of AGE-BSA on the secretion of IGFBPs in mineralised MC3T3E1 cultures. a Cells were incubated in serum-free DMEM
with either BSA (lanes 1, 3 and 5) or AGE-BSA (lanes 2, 4 and 6) at protein concentrations of 100 µg/ml (lanes 1 and 2), 200 µg/ml (lanes
3 and 4) or 500 µg/ml (lanes 5 and 6). After a 24-hour incubation, conditioned media were analysed for the presence of IGFBPs by west-
ern ligand blotting employing 125I-IGF-I as a ligand. Lane 7, 10 µl rat serum. Bands were evidenced by autoradiography. b Nitrocellulose
papers were cut into strips and counted in a gamma counter for semiquantification. Data for AGE-BSA are expressed as a percentage of
the corresponding control BSA condition, and given as the mean ± SEM (n=8). Differences between BSA and AGE-BSA are as follows:








in IGF-I secretion could contribute to the observed biolog-
ical effects, possibly as a consequence of the occupation of
AGE-specific receptors.
The use of the MC3T3E1 cell line, which progressively
differentiates through successive stages of osteoblastic
development, allowed us to further test our hypothesis. This
progressive development was confirmed in the present
study, by measurement of temporal changes in ALP activity
and formation of nodules of mineralisation. We have previ-
ously demonstrated that AGE-BSA modifies the prolifera-
tion (in 3-day cultures) and ALP activity (in 25-day cultures)
of this osteoblastic cell line, in a sequence similar to
UMR106 cells. That is, short incubations with AGE-modi-
fied proteins provoke an increase in these biological effects,
generally followed by a decrease when incubations with
AGE are prolonged [24]. Moreover, we have also found
AGE-specific receptors in these cells, which are differen-
tially regulated throughout the osteoblastic stages of devel-
opment, and whose half-maximal binding is similar to the
AGE doses needed for a biological effect [10].
MC3T3E1 cells in this study secreted basal IGF-I levels
which were in the order of the IGF-II concentration pro-
duced by human calvaria-derived bone cells [49]. In agree-
ment with previous reports both in MC3T3E1 cells [36] and
in a primary cultures of osteoblasts [50], we found biphasic
temporal changes in the cellular secretion of IGF-I: mini-
mum levels were observed in 15-day cultures, while the
maximum concentrations were attained in mineralised (25-
day) cultures (Table 1).
MC3T3E1 cells principally secrete IGFBP-2 and -5, as
well as a weak 24-kDa band which corresponds to IGFBP-
4. The two major binding proteins are indistinguishable by
ligand blot analysis, since they migrate as a single band with
an apparent molecular weight of 29 kDa. The relative secre-
tion of IGFBP-2 and -5 by this cell line has been found to be
dependent on the stage of osteoblastic differentiation [36]:
by immunoblot analysis, IGFBP-5 was found to peak
between days 8 and 14 of culture, decreasing thereafter. On
the other hand, in the same study IGFBP-2 increased con-
stantly until day 25 of culture (mineralised cells), and was
the predominant binding protein in the later stages of devel-
opment [36]. In our experiments, these cells secreted 29-
kDa binding proteins, most probably corresponding to vari-
able amounts of IGFBP-2 and -5.
In actively proliferating MC3T3E1 cells, AGE-modified
BSA induced a significant decrease in IGF-I secretion (Fig.
2a), and an increase in IGFBP levels (Fig. 4). IGFBP-2 has
been shown to inhibit the mitogenic effects of IGF-I in cer-
tain systems. In addition, recent studies have demonstrated
that IGFBP-5 secreted into the conditioned medium (but
unbound to the extracellular matrix [ECM]), inhibits the
mitogenic effect of IGF-I in smooth muscle cells [51].
Importantly, MC3T3E1 cells produce relatively low
amounts of ECM during their proliferative phase [37]. Thus,
both 29-kDa binding proteins may exhibit similar effects on
IGF-I-induced cell proliferation. Considering the great
AGE-induced inhibition of IGF-I secretion by these pre-
osteoblastic cells, and the increase in the total amount of
IGFBP detected by ligand blot, it is conceivable to suppose
that a diminished amount of free IGF-I should be available
for binding to specific type-I IGF receptors, provoking a
decrease in osteoblastic replication. This situation is com-
patible with the inhibition of MC3T3E1 proliferation ulti-
mately induced by AGE-BSA, which we have reported pre-
viously [24].
When MC3T3E1 osteoblasts attained the mature stage of
differentiation (15-day cultures), no significant effects were
observed by AGE-modified proteins on either IGF-I or
IGFBP secretion (Fig. 5). In addition, at this period of
MC3T3E1 osteoblastic development, we were not able to
detect any significant effects of AGE-BSA on ALP activity
(our unpublished observations).
Finally, in mineralised MC3T3E1 cells (25-day cultures),
AGE-BSA was found to increase the production of both
IGF-I (Fig. 2b) and IGFBP (Fig. 6). The effect on IGFBP
secretion showed a biphasic pattern which is in agreement
with our previous results on the AGE-induced ALP modula-
tion in mineralised MC3T3E1 osteoblasts. At this stage of
osteoblastic development, the 29-kDa band which we detect-
ed by ligand blot analysis probably represents IGFBP-2,
according to the western immunoblot observations of previ-
ous studies [36]. These changes in the secretion of IGF-I and
29-kDa IGFBPs by mineralising osteoblasts could be related
to our previous report of an ultimate decrease in ALP activ-
ity in such cells after their incubation with AGE-BSA [24],
and with other reports of an AGE-induced decrease in the
expression of several parameters of bone phenotype such as
ALP, osteocalcin, osteopontin, and nodule formation by
mineralised osteoblasts [19, 23].
From the presented results, it can be seen that differenti-
ated MC3T3E1 cells (15-day culture) show no AGE-
induced modifications on IGF or IGFBP secretion, and this
is coincident with a lack of alterations in the measured bio-
logical effects. On the other hand, the AGE-associated mod-
ulation of the IGF/IGFBP system, which we have found in
the proliferating and mineralised MC3T3E1 cell model,
could be associated with the observed dysregulation of
osteoblast development. Thus, this experimental model of
MC3T3E1 cells appears to support the concept that the bio-
logical effect of AGEs in osteoblastic cells, possibly initiat-
ed through a recognition of AGE structures by their specific
receptors, could be mediated by the IGF system in an
autocrine-paracrine manner.
In summary, our present observations provide evidence
for a direct effect of advanced glycation endproducts on the
secretion of IGF-I and its binding proteins, in a pattern
which depends on the stage of osteoblastic development.
They suggest a role for the IGF axis as a potential mediator
in the seemingly deleterious effects of AGE-modified pro-
teins on bone.
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